OliX Pharmaceuticals, Inc (KOSDAQ: 226950)
South Korea
· Delayed Price · Currency is KRW 16,490
-2,060 (-11.11%)
Dec 20, 2024, 9:00 AM KST
OliX Pharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 16,138 | 17,064 | 9,320 | 3,674 | 2,474 | 1,130 | Upgrade
|
| Revenue Growth (YoY) | 122.56% | 83.09% | 153.66% | 48.50% | 118.90% | 274.28% | Upgrade
|
| Cost of Revenue | 245.39 | 159.88 | 206.95 | 171.77 | 58.52 | 52.86 | Upgrade
|
| Gross Profit | 15,893 | 16,904 | 9,113 | 3,503 | 2,416 | 1,077 | Upgrade
|
| Selling, General & Admin | 14,235 | 14,178 | 12,346 | 11,488 | 8,227 | 6,665 | Upgrade
|
| Research & Development | 20,229 | 18,478 | 17,379 | 14,992 | 9,478 | 8,973 | Upgrade
|
| Other Operating Expenses | 587.41 | 570.74 | 657.94 | 395.85 | 310.7 | 211.29 | Upgrade
|
| Operating Expenses | 36,933 | 35,090 | 31,489 | 27,731 | 18,657 | 16,194 | Upgrade
|
| Operating Income | -21,041 | -18,185 | -22,376 | -24,229 | -16,241 | -15,117 | Upgrade
|
| Interest Expense | -4,062 | -3,492 | -2,930 | -2,431 | -239.07 | -5.61 | Upgrade
|
| Interest & Investment Income | 549.95 | 1,286 | 1,396 | 476.04 | 250.55 | 517.56 | Upgrade
|
| Earnings From Equity Investments | -616.51 | -900.91 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -90.6 | 14.62 | -127.59 | -23 | -14.69 | 47.8 | Upgrade
|
| Other Non Operating Income (Expenses) | -3,654 | 2,335 | -5,054 | -3,675 | -775.5 | 9.78 | Upgrade
|
| EBT Excluding Unusual Items | -28,914 | -18,943 | -29,092 | -29,881 | -17,020 | -14,547 | Upgrade
|
| Gain (Loss) on Sale of Investments | 411.89 | 438.97 | -36.12 | 11.17 | -3,491 | 301.27 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1,899 | -87.48 | 20.34 | -416.83 | - | 2.45 | Upgrade
|
| Other Unusual Items | 351.91 | 421.58 | - | 289.29 | - | - | Upgrade
|
| Pretax Income | -26,251 | -18,170 | -29,108 | -29,997 | -20,511 | -14,244 | Upgrade
|
| Income Tax Expense | -949.79 | 932.07 | -994.9 | -821.54 | -1,126 | 109.19 | Upgrade
|
| Earnings From Continuing Operations | -25,302 | -19,102 | -28,113 | -29,176 | -19,385 | -14,353 | Upgrade
|
| Earnings From Discontinued Operations | - | - | 6,225 | -1,102 | - | - | Upgrade
|
| Net Income to Company | -25,302 | -19,102 | -21,888 | -30,278 | -19,385 | -14,353 | Upgrade
|
| Minority Interest in Earnings | - | - | 2,392 | 563.24 | - | - | Upgrade
|
| Net Income | -25,302 | -19,102 | -19,495 | -29,715 | -19,385 | -14,353 | Upgrade
|
| Net Income to Common | -25,302 | -19,102 | -19,495 | -29,715 | -19,385 | -14,353 | Upgrade
|
| Shares Outstanding (Basic) | 16 | 14 | 14 | 14 | 13 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 14 | 14 | 14 | 13 | 13 | Upgrade
|
| Shares Change (YoY) | 19.09% | 5.30% | 0.13% | 4.06% | 1.00% | 12.26% | Upgrade
|
| EPS (Basic) | -1534.32 | -1323.81 | -1422.69 | -2171.18 | -1473.86 | -1102.23 | Upgrade
|
| EPS (Diluted) | -1534.32 | -1324.00 | -1422.69 | -2171.18 | -1474.00 | -1102.23 | Upgrade
|
| Free Cash Flow | -34,838 | -29,995 | -32,916 | -20,344 | -4,546 | -11,740 | Upgrade
|
| Free Cash Flow Per Share | -2112.63 | -2078.73 | -2402.08 | -1486.45 | -345.62 | -901.59 | Upgrade
|
| Gross Margin | 98.48% | 99.06% | 97.78% | 95.33% | 97.63% | 95.32% | Upgrade
|
| Operating Margin | -130.38% | -106.57% | -240.07% | -659.40% | -656.41% | -1337.38% | Upgrade
|
| Profit Margin | -156.78% | -111.94% | -209.17% | -808.70% | -783.44% | -1269.79% | Upgrade
|
| Free Cash Flow Margin | -215.88% | -175.77% | -353.16% | -553.66% | -183.72% | -1038.65% | Upgrade
|
| EBITDA | -18,408 | -15,543 | -20,301 | -22,599 | -15,101 | -14,341 | Upgrade
|
| EBITDA Margin | -114.06% | -91.09% | -217.82% | - | - | - | Upgrade
|
| D&A For EBITDA | 2,633 | 2,642 | 2,075 | 1,630 | 1,141 | 775.52 | Upgrade
|
| EBIT | -21,041 | -18,185 | -22,376 | -24,229 | -16,241 | -15,117 | Upgrade
|
| EBIT Margin | -130.38% | -106.57% | -240.07% | - | - | - | Upgrade
|
| Advertising Expenses | - | 77.82 | 73.74 | 63.88 | 95.55 | 104.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.